Skip to main navigation Skip to search Skip to main content

The Safety, Tolerability, and Immunogenicity of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Subject Infected With HIV Who are Either Previously Vaccinated or Vaccinia Naive: A Double-Blind, Placebo-Controlled, Phase 1/2 Study

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/05 → 8/31/10

Funding

  • Acambis Inc: $5,670.00